Page last updated: 2024-10-23

aspirin and Barrett Epithelium

aspirin has been researched along with Barrett Epithelium in 58 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

ExcerptRelevanceReference
"Non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), low-dose aspirin and statins may decrease the risk of oesophageal adenocarcinoma (OAC) among patients with Barrett's oesophagus (BO)."7.81NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. ( Coloma, PM; Kuipers, EJ; Masclee, GM; Spaander, MC; Sturkenboom, MC, 2015)
"Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with Barrett's esophagus."7.80Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model. ( Cebrián, C; Esquivias, P; García-González, MA; Lanas, A; Morandeira, A; Ortego, J; Piazuelo, E; Santander, S, 2014)
"Non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), low-dose aspirin and statins may decrease the risk of oesophageal adenocarcinoma (OAC) among patients with Barrett's oesophagus (BO)."3.81NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. ( Coloma, PM; Kuipers, EJ; Masclee, GM; Spaander, MC; Sturkenboom, MC, 2015)
"Data suggest that aspirin, statins, or a combination of the two drugs may lower the progression of Barrett's esophagus to esophageal adenocarcinoma."3.80Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. ( Choi, SE; Hur, C; Kong, CY; Perzan, KE; Tramontano, AC, 2014)
"Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with Barrett's esophagus."3.80Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model. ( Cebrián, C; Esquivias, P; García-González, MA; Lanas, A; Morandeira, A; Ortego, J; Piazuelo, E; Santander, S, 2014)
" Male gender, smoking, alcohol drinking, consumption of coffee, large waist circumference, infrequent medication of antacids, aspirin and NSAIDs, infrequent and mild GERD symptoms were all significantly associated with ED on univariate analysis."3.77[Clinical characteristics of gastroesophageal reflux disease with esophageal injury in korean: focusing on risk factors]. ( Cho, KB; Jang, BI; Jeon, SW; Jung, JT; Jung, MK; Kim, ES; Kim, EY; Kim, KO; Kim, SK; Kwon, JG; Lee, JH; Lee, SH; Lee, SJ; Park, CK; Park, KS; Seo, HE; Yang, CH, 2011)
"Although evidence suggests that aspirin and celecoxib may reduce the risk of esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE), these drugs can also cause harmful side effects."3.74Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. ( Broughton, DE; Gazelle, GS; Hur, C; Nishioka, NS; Ozanne, E; Yachimski, P, 2008)
"Candidates for chemoprevention in Barrett's esophagus have long been suggested and there has been observational data to support many drugs, including statins, hormone replacement therapy, metformin, proton pump inhibitor therapy, and aspirin."2.72Current Status of Chemoprevention in Barrett's Esophagus. ( El-Serag, HB; Moayyedi, P, 2021)
"To compare the effects of aspirin and rofecoxib when administered with esomeprazole on prostaglandin E(2) production, cyclo-oxygenase-2 expression and proliferating cell nuclear antigen expression in patients with Barrett's oesophagus."2.72The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett's oesophagus. ( Kaur, B; Levine, D; Sood, S; Traxler, B; Triadafilopoulos, G; Weston, A, 2006)
"Abdominal obesity, independently of gastroesophageal reflux disease symptoms, is associated with increased risk of Barrett's esophagus and this association is likely mediated by high levels of leptin and insulin."2.53Determination of risk for Barrett's esophagus and esophageal adenocarcinoma. ( Thrift, AP, 2016)
"Barrett's metaplasia is one of the commonest premalignant lesions in the western world following colorectal adenomas."2.47Acid reflux and oesophageal cancer. ( Jankowski, J; Nicholson, A, 2011)
"In patients with Barrett's esophagus, medical treatment is necessary for the control of reflux symptom, healing of accompanying erosive esophagitis, and prevention of carcinogenesis."2.43[Medical treatment of Barrett's esophagus]. ( Kinoshita, Y; Yuki, T, 2005)
"Barrett esophagus is a premalignant change of the esophagus; however, malignant transformation to esophageal adenocarcinoma is rare in patients without dysplasia."1.72Barrett Esophagus: Rapid Evidence Review. ( Bryce, C; Bucaj, M; Gazda, R, 2022)
"Cases had a new diagnosis of Barrett's esophagus between October 2002 and September 2005; controls were members without a diagnosis of Barrett's esophagus."1.42Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus. ( Corley, DA; Schneider, JL; Zhao, WK, 2015)
"18), and no dose-response effects were present in either analysis."1.37The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. ( Green, AC; Pandeya, N; Smith, KJ; Thrift, AP; Webb, PM; Whiteman, DC, 2011)
"examined Barrett's esophagus patient preferences for cancer chemoprevention with either aspirin or celecoxib."1.35Chemoprevention and Barrett's esophagus: decisions, decisions. ( Falk, GW; Jankowski, J, 2008)
"It has been suggested that Barrett's esophagus (BE) is associated with an increased risk of developing colorectal neoplasia, but this has not been reported consistently."1.33Colorectal neoplasia in veterans is associated with Barrett's esophagus but not with proton-pump inhibitor or aspirin/NSAID use. ( Kuipers, EJ; Sahbaie, P; Siersema, PD; Simpson, PW; Steyerberg, EW; Triadafilopoulos, G; Yu, S, 2006)
"In total, 230 reflux esophagitis, 224 Barrett's esophagus, and 227 esophageal adenocarcinoma and 260 population controls were recruited."1.33Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. ( Anderson, LA; Comber, H; Ferguson, HR; Johnston, BT; McGuigan, J; Murphy, SJ; Murray, LJ; Reynolds, JV; Watson, RG, 2006)
"Uninvestigated dyspepsia is common in family practice."1.32The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. ( Armstrong, D; Barkun, AN; Chakraborty, B; Chiba, N; Daniels, S; Escobedo, S; Sinclair, P; Thomson, AB; Van Zanten, SJ; White, RJ, 2003)
"Aspirin therapy was more effective and less costly than no therapy, resulting in 0."1.32Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. ( Gazelle, GS; Hur, C; Nishioka, NS, 2004)

Research

Studies (58)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (3.45)18.2507
2000's20 (34.48)29.6817
2010's33 (56.90)24.3611
2020's3 (5.17)2.80

Authors

AuthorsStudies
Bryce, C1
Bucaj, M1
Gazda, R1
Zhang, T1
Wang, Q1
Ma, WY1
Wang, K2
Chang, X1
Johnson, ML1
Bai, R1
Bode, AM1
Foster, NR2
Falk, GW3
Limburg, PJ2
Iyer, PG1
Dong, Z1
Moayyedi, P3
El-Serag, HB3
Zhao, Z1
Yin, Z1
Zhang, C1
Huo, X1
Zhang, X1
Yu, C1
Cheng, E1
Zhang, Q1
Dunbar, KB1
Pham, TH1
Lynch, JP1
Wang, DH1
Bresalier, RS1
Spechler, SJ1
Souza, RF1
Thota, PN1
Hvid-Jensen, F1
Drewes, AM1
Jankowski, JAZ1
de Caestecker, J1
Love, SB1
Reilly, G1
Watson, P1
Sanders, S1
Ang, Y1
Morris, D1
Bhandari, P1
Brooks, C1
Attwood, S2
Harrison, R2
Barr, H2
Husain, NS1
Marshall, JK1
Fitzgerald, RC1
Corley, DA4
Choi, SE1
Perzan, KE1
Tramontano, AC1
Kong, CY2
Hur, C5
Peura, DA1
Wilcox, CM1
Cowie, A1
Noble, F1
Underwood, T1
Esquivias, P1
Cebrián, C1
Morandeira, A1
Santander, S1
Ortego, J1
García-González, MA1
Lanas, A1
Piazuelo, E1
Schneider, JL2
Zhao, WK1
Masclee, GM1
Coloma, PM1
Spaander, MC1
Kuipers, EJ2
Sturkenboom, MC1
Goldberg, A1
Gerkin, RD1
Young, M1
Beales, IL2
Dearman, L2
Vardi, I2
Loke, Y1
Thrift, AP3
Anderson, LA2
Murray, LJ2
Cook, MB1
Shaheen, NJ2
Rubenstein, JH1
Vaughan, TL1
Whiteman, DC2
Jankowski, J7
Broughton, DE1
Ozanne, E1
Yachimski, P1
Nishioka, NS2
Gazelle, GS2
Gatenby, PA1
Ramus, JR1
Caygill, CP1
Winslet, MC1
Watson, A1
deCaestecker, J1
Rizvi, S1
Demars, CJ2
Comba, A1
Gainullin, VG1
Rizvi, Z1
Almada, LL1
Lomberk, G1
Fernández-Zapico, ME1
Buttar, NS2
Dall'Olmo, L1
Moja, L1
Jankowski, JA2
Hooper, PA1
Triadafilopoulos, G3
Lombard, CM1
Jobe, BA1
Wang, F1
Lv, ZS1
Fu, YK1
Scholl, S1
Dellon, ES1
Lee, SJ1
Jung, MK1
Kim, SK1
Jang, BI1
Lee, SH1
Kim, KO1
Kim, ES1
Cho, KB1
Park, KS1
Kim, EY1
Jung, JT1
Kwon, JG1
Lee, JH1
Yang, CH1
Park, CK1
Seo, HE1
Jeon, SW1
Nicholson, A1
Pandeya, N1
Smith, KJ1
Green, AC1
Webb, PM1
Omer, ZB1
Ananthakrishnan, AN1
Nattinger, KJ1
Cole, EB1
Lin, JJ1
Thiagarajan, P1
Sanders, DS1
Grabsch, H1
Bateman, A1
Going, J1
Goldin, R1
Mapstone, N1
Novelli, M1
Walker, MM1
Ziegler, KL1
Romero, Y1
Marcon, NE1
Schnell, T1
Sharma, P1
Cruz-Correa, MR1
Fleischer, DE1
Chak, A1
Devault, KR1
Weinberg, DS1
Della'Zanna, G1
Richmond, E1
Smyrk, TC1
Mandrekar, SJ1
Inadomi, JM1
Thomson, AB1
Barkun, AN1
Armstrong, D1
Chiba, N1
White, RJ1
Daniels, S1
Escobedo, S1
Chakraborty, B1
Sinclair, P1
Van Zanten, SJ1
Füessl, HS2
Garber, K1
Raj, A1
Kinoshita, Y1
Yuki, T1
Sharma, S1
Siersema, PD1
Yu, S1
Sahbaie, P1
Steyerberg, EW1
Simpson, PW1
Kaur, B1
Sood, S1
Traxler, B1
Levine, D1
Weston, A1
Johnston, BT1
Watson, RG1
Murphy, SJ1
Ferguson, HR1
Comber, H1
McGuigan, J1
Reynolds, JV1
Konturek, PC1
Kania, J1
Burnat, G1
Hahn, EG1
Leedham, S1
Morgan, G2

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized, Double-Blinded Phase II Trial of Esomeprazole Versus Esomeprazole + Two Doses of Aspirin in Barrett's Esophagus Patients[NCT00474903]Phase 2122 participants (Actual)Interventional2007-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Mean Tissue Prostaglandin E2 (PGE2) Concentration as Determined From Barrett's Research Mucosal Biopsy Samples

The mean tissue PGE2 is reported for each Arm. (NCT00474903)
Timeframe: Baseline to 30 days after completion of study treatment

Interventionpg/mL (Mean)
Arm I (Placebo, Esomeprazole Magnesium)-67.6
Arm II (Low-dose Aspirin, Placebo, Esomeprazole Magnesium)-123.9
Arm III (Higher-dose Aspirin, Palcebo, Esomeprazole Magnesium)-174.9

Toxicity

Toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to the interventional agent, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The number of patients reporting adverse events will be tabulated by grade. (NCT00474903)
Timeframe: Up to 30 days after completion of study treatment

,,
Interventionparticipants (Number)
Grade 3 or HigherGrade 4 or Higher
Arm I (Placebo, Esomeprazole Magnesium)00
Arm II (Low-dose Aspirin, Placebo, Esomeprazole Magnesium)10
Arm III (Higher-dose Aspirin, Palcebo, Esomeprazole Magnesium)10

Reviews

13 reviews available for aspirin and Barrett Epithelium

ArticleYear
Current Status of Chemoprevention in Barrett's Esophagus.
    Gastrointestinal endoscopy clinics of North America, 2021, Volume: 31, Issue:1

    Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Chemoprevention; Drug Therapy, Combination; Esophageal N

2021
Lifestyle interventions can reduce the risk of Barrett's esophagus: a systematic review and meta-analysis of 62 studies involving 250,157 participants.
    Cancer medicine, 2021, Volume: 10, Issue:15

    Topics: Adenocarcinoma; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Aspirin; B

2021
Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.
    Postgraduate medicine, 2014, Volume: 126, Issue:1

    Topics: Aspirin; Barrett Esophagus; Cardiovascular Diseases; Colorectal Neoplasms; Drug Combinations; Gastro

2014
Strategies to improve outcomes in esophageal adenocarcinoma.
    Expert review of anticancer therapy, 2014, Volume: 14, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents; Aspirin; Barrett Esophagus; Combined Modality Therapy; Cytodi

2014
Reduced Risk of Barrett's Esophagus in Statin Users: Case-Control Study and Meta-Analysis.
    Digestive diseases and sciences, 2016, Volume: 61, Issue:1

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-C

2016
Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
    Current opinion in gastroenterology, 2016, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Disease Progres

2016
Chemoprevention in Barrett's esophagus: A pill a day?
    Gastrointestinal endoscopy clinics of North America, 2011, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Diet; Esophagea

2011
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2011, Volume: 24, Issue:5

    Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-Control St

2011
Acid reflux and oesophageal cancer.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 185

    Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cyclooxygenase 2; Esophageal Neoplasms; Esophagitis; Gas

2011
Aspirin and NSAIDs; benefits and harms for the gut.
    Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:2

    Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cardiovascular Disease

2012
Acid suppression and chemoprevention in Barrett's oesophagus.
    Digestive diseases (Basel, Switzerland), 2004, Volume: 22, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Enzyme Inhib

2004
[Medical treatment of Barrett's esophagus].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63, Issue:8

    Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cycloo

2005
Dilemmas in managing Barrett's oesophagus.
    Drug and therapeutics bulletin, 2006, Volume: 44, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Endoscopy, Gastrointestinal; Ga

2006

Trials

6 trials available for aspirin and Barrett Epithelium

ArticleYear
Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development.
    EBioMedicine, 2019, Volume: 49

    Topics: Adenocarcinoma; Animals; Aspirin; Barrett Esophagus; Carcinogenesis; Cell Line, Tumor; Cell Prolifer

2019
Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.
    Lancet (London, England), 2018, 08-04, Volume: 392, Issue:10145

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Drug A

2018
Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort.
    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2009, Volume: 18, Issue:5

    Topics: Adenocarcinoma; Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cohort Studies; Demography; Eso

2009
Comparing virtual with conventional microscopy for the consensus diagnosis of Barrett's neoplasia in the AspECT Barrett's chemoprevention trial pathology audit.
    Histopathology, 2012, Volume: 61, Issue:5

    Topics: Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Disease Progression; Esomeprazole; Esophageal Neoplas

2012
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.
    Gastroenterology, 2012, Volume: 143, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Barrett Esophagus; Biomarkers; Biopsy; Cyclooxygenase Inhib

2012
The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett's oesophagus.
    Alimentary pharmacology & therapeutics, 2006, Apr-01, Volume: 23, Issue:7

    Topics: Adult; Aged; Aspirin; Barrett Esophagus; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhi

2006

Other Studies

39 other studies available for aspirin and Barrett Epithelium

ArticleYear
Barrett Esophagus: Rapid Evidence Review.
    American family physician, 2022, Volume: 106, Issue:4

    Topics: Adenocarcinoma; Anti-Inflammatory Agents; Aspirin; Barrett Esophagus; Esophageal Neoplasms; Humans;

2022
Aspirin prevents NF-κB activation and CDX2 expression stimulated by acid and bile salts in oesophageal squamous cells of patients with Barrett's oesophagus.
    Gut, 2018, Volume: 67, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Bile Acids and Salts; CDX2 Tran

2018
Aspirin: the miracle drug?
    Clinical and translational gastroenterology, 2018, 05-02, Volume: 9, Issue:5

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Female; Humans; Middle Ag

2018
Should aspirin and PPIs be recommended for patients with Barrett's oesophagus?
    Lancet (London, England), 2018, 08-04, Volume: 392, Issue:10145

    Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Esophageal Neoplasms; Esophagus; Humans; Proton Pump Inh

2018
Chemoprevention of Barrett's oesophagus: a step closer with PPIs and aspirin.
    Nature reviews. Clinical oncology, 2018, Volume: 15, Issue:12

    Topics: Aspirin; Barrett Esophagus; Chemoprevention; Drug Combinations; Humans; Proton Pump Inhibitors; Rand

2018
In Barrett esophagus, high- vs low-dose esomeprazole improved clinical outcomes; aspirin vs no aspirin did not.
    Annals of internal medicine, 2018, 11-20, Volume: 169, Issue:10

    Topics: Aspirin; Barrett Esophagus; Drug Therapy, Combination; Esomeprazole; Humans; Proton Pump Inhibitors

2018
Will a Proton Pump Inhibitor and an Aspirin Keep the Doctor Away for Patients With Barrett's Esophagus?
    Gastroenterology, 2019, Volume: 156, Issue:5

    Topics: Aspirin; Barrett Esophagus; Esomeprazole; Esophageal Neoplasms; Humans; Proton Pump Inhibitors

2019
Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.
    Cancer prevention research (Philadelphia, Pa.), 2014, Volume: 7, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Aspirin; Barrett Esophagus; Case-Control Studies; Chemoprev

2014
Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model.
    Oncology reports, 2014, Volume: 31, Issue:6

    Topics: Adenocarcinoma; Animals; Aspirin; Barrett Esophagus; Dinoprostone; Disease Models, Animal; Esophagea

2014
Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; California; Case-C

2015
NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
    BMJ open, 2015, Jan-29, Volume: 5, Issue:1

    Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-Control St

2015
Medical Prevention of Barrett's Esophagus: Effects of Statins, Aspirin, Non-aspirin NSAIDs, Calcium, and Multivitamins.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:7

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Calcium; Case-Control Stu

2015
Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.
    The American journal of gastroenterology, 2016, Volume: 111, Issue:11

    Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-Cont

2016
Chemoprevention and Barrett's esophagus: decisions, decisions.
    The American journal of gastroenterology, 2008, Volume: 103, Issue:10

    Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc

2008
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
    The American journal of gastroenterology, 2008, Volume: 103, Issue:10

    Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc

2008
Aspirin in the primary prevention of vascular disease.
    Lancet (London, England), 2009, Sep-12, Volume: 374, Issue:9693

    Topics: Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Drug Therapy, Combination; Evidence-Based Medicine; H

2009
Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis.
    Cancer research, 2010, Sep-01, Volume: 70, Issue:17

    Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cell Growth Processes;

2010
Treatment for non-dysplastic Barrett's oesophagus: a well-informed, demanding patient.
    Internal and emergency medicine, 2010, Volume: 5, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Fundoplication; Humans; Male; M

2010
"War and Peace" with Barrett's esophagus.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:4

    Topics: Adenocarcinoma; Aged; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Barrett Esophagus; Celeco

2011
Treatment of GERD and proton pump inhibitor use in the elderly: practical approaches and frequently asked questions.
    The American journal of gastroenterology, 2011, Volume: 106, Issue:3

    Topics: Adenocarcinoma; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Aspirin; Barrett Esop

2011
[Clinical characteristics of gastroesophageal reflux disease with esophageal injury in korean: focusing on risk factors].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2011, May-25, Volume: 57, Issue:5

    Topics: Adolescent; Adult; Aged; Alcohol Drinking; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Aspiri

2011
The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus.
    Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:10

    Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Ster

2011
Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2012, Volume: 10, Issue:7

    Topics: Aged; Anti-Inflammatory Agents; Aspirin; Barrett Esophagus; Case-Control Studies; Chemoprevention; F

2012
Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma.
    European journal of gastroenterology & hepatology, 2012, Volume: 24, Issue:8

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett E

2012
Is 325 mg of prevention worth a pound of cure?
    Gastroenterology, 2012, Volume: 143, Issue:4

    Topics: Aspirin; Barrett Esophagus; Cyclooxygenase Inhibitors; Dinoprostone; Female; Humans; Male; Omeprazol

2012
The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study.
    Alimentary pharmacology & therapeutics, 2003, Jun-15, Volume: 17, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barret

2003
[Heartburn without esophagitis. Symptoms more important than the finding?].
    MMW Fortschritte der Medizin, 2003, Sep-25, Volume: 145, Issue:39

    Topics: Androstadienes; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ul

2003
Aspirin for cancer chemoprevention: still a headache?
    Journal of the National Cancer Institute, 2004, Feb-18, Volume: 96, Issue:4

    Topics: Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cost-Benefit Analysis; Cyclooxygenase Inhibitor

2004
Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
    Journal of the National Cancer Institute, 2004, Feb-18, Volume: 96, Issue:4

    Topics: Aged; Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cost-Benefit Analysis; Drug Costs; Esopha

2004
Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
    Journal of the National Cancer Institute, 2004, Jun-02, Volume: 96, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Cost-Benefit Analysis; D

2004
Upper gastrointestinal bleeding after hip and knee arthroplasty.
    Orthopedics, 2006, Volume: 29, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplast

2006
Colorectal neoplasia in veterans is associated with Barrett's esophagus but not with proton-pump inhibitor or aspirin/NSAID use.
    Gastrointestinal endoscopy, 2006, Volume: 63, Issue:4

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Biopsy; California; Color

2006
Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
    Cancer research, 2006, May-01, Volume: 66, Issue:9

    Topics: Acetaminophen; Adenocarcinoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Asp

2006
NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2006, Volume: 57 Suppl 12

    Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Barrett Esophagus; Casp

2006
The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus--the good, the bad, and the flawed!
    The American journal of gastroenterology, 2007, Volume: 102, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Chemoprevent

2007
Biomarkers identified to predict esophageal cancer susceptibility and aspirin found to lower cancer risk.
    Future oncology (London, England), 2007, Volume: 3, Issue:2

    Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Biomarkers, Tum

2007
[Family practice highlights of stomach, liver and intestinal reference points. Your arsenal against abdominal problems].
    MMW Fortschritte der Medizin, 2007, Nov-29, Volume: 149, Issue:48

    Topics: Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Family Practi

2007
Relationship between colorectal and esophageal cancer.
    Diseases of the colon and rectum, 1996, Volume: 39, Issue:2

    Topics: Aspirin; Barrett Esophagus; Colorectal Neoplasms; Esophageal Neoplasms; Humans

1996
Correspondence re: R. Kim et al., Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol., Biomark. Prev., 6: 369-377, 1997.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 1998, Volume: 7, Issue:3

    Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cell Transforma

1998